GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity

Bibliography

• Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522-5
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Drugs on the horizon for diabesity. Curr Diab Rep 2005;5:353-9
   PubMedGoogle Scholar
• Cefalu WT, Waldman S, Ryder S. Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: Rationale and specific agents. Clin Pharmacol Ther 2007;81:636-49
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in Type 2 diabetes mellitus. Drugs 2005;65:385-411
   PubMed Web of Science ®Google Scholar
• Overington J, Al-Lazikani PB, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6
   PubMed Web of Science ®Google Scholar
• Schlyer S, Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today 2006;11:481-93
   PubMed Web of Science ®Google Scholar
• Bjenning C, Al-Shamma H, Thomsen W, et al. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes. Curr Opin Invest Drugs 2004;5:1051-62
   PubMedGoogle Scholar
• Schiöth HB. G protein-coupled receptors in regulation of body weight. CNS Neurol Disorders Drug Targets 2006;5:241-9
   PubMedGoogle Scholar
• Fyfe MCT, Overton HA, Procter MJ, et al. New nonpeptide-binding GPCRs as targets for diabetes and the metabolic syndrome. Annu Rep Med Chem 2007;42:129-45
   Web of Science ®Google Scholar
• Morphy R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J Med Chem 2006;49:2969-78
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Höglund PJ, Gloriam DEI, et al. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 2003;554:381-8
   PubMed Web of Science ®Google Scholar
• Bonini JA, Borowsky BE, Adham N, et al. DNA encoding SNORF25 receptor. US6221660 (2001)
   Google Scholar
• Bonini JA, Borowsky BE, Adham N, et al. Methods of identifying compounds that bind to SNORF25 receptors. US6468756 (2002)
   Google Scholar
• Jones RM, Semple G, Fioravanti B, et al. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycaemia. WO2004065380 (2004)
   Google Scholar
• Takeda S, Kadowaki S, Haga T, et al. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 2002;520:97-101
   PubMed Web of Science ®Google Scholar
• Davey J. G-protein-coupled receptors: new approaches to maximise the impact of GPCRs in drug discovery. Exp Opin Ther Targets 2004;8:165-70
   PubMed Web of Science ®Google Scholar
• Griffin G. Methods for identification of modulators of OSGPR116 activity. US7083933 (2006)
   Google Scholar
• Chu Z, Carroll C, Gutierrez V, et al. AR231453 mediates improved glycaemic control exclusively via GDIR/GPR119. Keystone Symposium [abstract 117]. Diabetes: Molecular Genetics, Signalling Pathways and Integrated Physiology. Keystone, Colorado, USA; 2007
   Google Scholar
• Chu Z, Jones R, Chen R, et al. Novel lipid amide activators of GDIR/GPR119 and their role in glucose homeostasis [abstract 230]. Keystone Symposium. Diabetes: Molecular Genetics, Signalling Pathways and Integrated Physiology. Keystone, Colorado, USA; 2007
   Google Scholar
• Ohishi T, Takasaki J, Matsumoto M, et al. Method of screening remedy for diabetes. EP1338651 (2003)
   Google Scholar
• Overton HA, Fyfe MCT, Reynet C. GPR119, a novel G-protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 2007: published online 26 November 2007, doi:10.1038/sj.bpj.0707529
   PubMedGoogle Scholar
• Fyfe MCT, Overton HA, White JR, et al. Discovery of novel, orally active, synthetic GPR119 agonists as potential agents for treatment of obesity and associated metabolic disorders. Diabetes 2006;55(Suppl 1):346-OR
   Google Scholar
• Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005;326:744-51
   PubMed Web of Science ®Google Scholar
• Chu Z-L, Leonard JN, Al-Shamma HA, Jones RM. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level. WO2006076231 (2006)
   Google Scholar
• Chu Z-L, Jones RM, He H, et al. A role for β-cell-expressed GPR119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148:2601-9
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Inoue H, Kawakami S, et al. Expression and distribution of GPR119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem Biophys Res Commun 2006;351:474-80
   PubMed Web of Science ®Google Scholar
• Fyfe MCT, White J, Widdowson PS, et al. GPR119 agonists are potential novel oral agents for the treatment of diabesity. Diabetes 2007;56(Suppl 1):532-P
   Google Scholar
• Drucker DJ, Jin T, Asa SL, et al. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enterondocrine cell line. Mol Endocrinol 1994;8:1646-55
   PubMed Web of Science ®Google Scholar
• Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3:167-75
   PubMed Web of Science ®Google Scholar
• Fujimoto WY, Metz SA. Phasic effects of glucose, phospholipase A2 and lysophospholipids on insulin secretion. Endocrinology 1987;120:1750-7
   PubMed Web of Science ®Google Scholar
• Rodríguez de Fonseca FR, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001;414:209-12
   PubMed Web of Science ®Google Scholar
• Fu J, Gaetani S, Oveisi F, et al. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 2003;425:90-3
   PubMed Web of Science ®Google Scholar
• Proulx K, Cota D, Castaneda TR, et al. Mechanisms of oleoylethanolamide (OEA)-induced changes in feeding behaviour and motor activity. Am J Physiol 2005;289:R729-37
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen M, Georgeson KE, Harmon CM. Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. Am J Physiol 2007;292:R235-41
   Web of Science ®Google Scholar
• Fyfe MCT, Babbs AJ, Bertram LS, et al. Synthesis, SAR, and in vivo efficacy of novel GPR119 agonists with a 4-[3-(4-methanesulfinylphenoxy)propyl]-1-Boc-piperidine core. Abstr Papers 234th National ACS Meeting; 2007 August 19 – 23; Boston, MA, USA; MEDI-062
   Google Scholar
• Furman B, Pyne N, Flatt P, O'Harte F. Targeting beta-cell cyclic 3′5′ adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. J Pharm Pharmacol 2004;56:1477-92
   PubMed Web of Science ®Google Scholar
• Lan H, Vassileva G, Corona A, et al. Mice lacking GPR119 maintain metabolic homeostasis [abstract 253]. Keystone Symposium. Diabetes: Molecular Genetics, Signalling Pathways and Integrated Physiology. Keystone, Colorado, USA; 2007
   Google Scholar
• Brubaker PL, Schloos J, Drucker DJ. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 1998;139:4108-14
   PubMed Web of Science ®Google Scholar
• Jones RM. Discovery of agonists of the glucose dependent insulinotropic receptor, GPR119, a pancreatic beta-cell oGPCR, for the treatment of NIDDM Abstr Papers 232nd National ACS Meeting; 2006 September 10 – 14; San Francisco, CA, USA; MEDI-275
   Google Scholar
• Drucker DJ. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharmaceut Des 2001;7:1399-412
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 2002;107:1-13
   PubMed Web of Science ®Google Scholar
• Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004;95:252-62
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005;48:612-5
   PubMed Web of Science ®Google Scholar
• Holst JJ. Glucagon-like peptide-1: from extract to agent. Diabetologia 2006;49:253-60
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology 2004;145:2653-9
   PubMed Web of Science ®Google Scholar
• Koh G, Suh KS, Chon S, et al. Elevated cAMP level attenuates 2-deoxy-D-ribose induced oxidative damage in pancreatic beta-cells. Arch Biochem Biophys 2005;438:70-9
   PubMed Web of Science ®Google Scholar
• Kwon G, Pappan KL, Marshall CA, et al. cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A and cAMP-guanine nucleotide exchange factor-dependent pathways in β-cells. J Biol Chem 2004;279:8938-45
   PubMed Web of Science ®Google Scholar
• Fyfe MCT, Widdowson P. Use of GPCR agonists to prevent progression of diabetes. WO2007138362 (2007)
   Google Scholar
• Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002;440:269-79
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
   PubMed Web of Science ®Google Scholar
• Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 2005;10:703-10
   PubMed Web of Science ®Google Scholar
• Madiraju SRM, Poitout V. GPCRs and insulin secretion: 119 and counting. Endocrinology 2007;148:2598-600
   PubMed Web of Science ®Google Scholar
• Mealy NE, Lupone B. Endocrine disorders. Drugs Fut 2006;31:719-50
   Web of Science ®Google Scholar
• Unniappan S, Mcintosh CH, Demuth HU, et al. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia 2006;49:1915-23
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-7
   PubMed Web of Science ®Google Scholar
• Højberg PV, Vilsbøll T, Knop FK, et al. Four weeks of near-normalization of blood glucose restores the insulin response to GIP and improves the insulin response to GLP-1 in patients with type 2 diabetes. Diabetes 2007;56(Suppl 1):1455-P
   Google Scholar
• Chu Z-L, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed GPR119 in glycemic control by enhancing GLP-1 and GIP release. Endocrinology 2008: published online 17 January 2008, doi:10.1210/en.2007-0966
   Google Scholar